BEDFORD, Mass., Sept. 10 /PRNewswire/ -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the appointment of James Nichols, Ph.D., as executive vice president of corporate development. In the newly created position, Dr. Nichols will have responsibilities in the areas of corporate strategy, business development, program management and business operations. Dr. Nichols will report to Paul Rubin, M.D., president and CEO of Resolvyx.
“Resolvyx is delighted to welcome Jamie, who brings an outstanding background in scientific innovation, product development, commercial strategy and business development,” said Dr. Rubin. “Jamie’s diverse capabilities further strengthen our experienced management team as we continue to advance the breakthrough therapeutic potential of resolvins to address unmet patient needs.”
Prior to joining Resolvyx, Dr. Nichols was vice president of therapeutics at CombinatoRx, Inc. In that role, he oversaw multiple R&D programs from discovery through phase II development across a range of therapeutic areas including inflammation, metabolic disease, dermatology, and ophthalmology. Previously, Dr. Nichols was a consultant at Braun Consulting, a healthcare- focused consulting firm (now acquired by Fair Isaac), where he advised senior executives in the biopharmaceutical industry on commercialization and development strategy.
Dr. Nichols graduated from Columbia University and earned his Ph.D. in neuroscience from the University of Pennsylvania. He was subsequently a Helen Hay Whitney Postdoctoral Fellow in neurobiology at Stanford University.
“Resolvins represent a breakthrough approach to fighting disease and offer tremendous promise to transform the treatment of many serious illnesses. I am very pleased to join Resolvyx’s management team and look forward to helping the company pursue a broad range of strategic development opportunities,” said Dr. Nichols.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately held biotechnology company dedicated to the development and commercialization of novel therapies to treat inflammatory diseases. The company’s key technologies are based on small molecules derived from the enzymatic oxidation of omega-3 fatty acids. These small molecules, called resolvins, have been shown to have significant anti- inflammatory effects in multiple models of human disease processes. Resolvyx’s drug R&D programs are focused on developing resolvin-based compounds to treat a range of both rare and highly prevalent inflammatory diseases. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive patent portfolio.
The company’s headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.
Resolvyx Pharmaceuticals, Inc.
CONTACT: Company Contact, James Nichols, EVP, Corporate Development,Resolvyx Pharmaceuticals, +1-781-541-5068, jnichols@resolvyx.com; or MediaContact, Stephen Zoegall of Berry & Company Public Relations for ResolvyxPharmaceuticals, Inc., +1-212-253-8881, szoegall@berrypr.com
Web site: http://www.resolvyx.com/
